Terumo subsidiary MicroVention announced recent one-year study results supporting the use of its nitinol WEB 17 occlusion device.
The company shared results from its multicenter, prospective CLEVER study evaluating WEB 17. It looked at the device in ruptured and unruptured aneurysms. The study aimed to understand the safety and effectiveness of the newest, smallest WEB system.
MicroVention’s WEB platform offers a single-device solution for aneurysms. The intrasaccular embolization system minimizes the need for a dual antiplatelet regimen required for intraluminal therapies.
CLEVER evaluated 163 patients across 17 European centers. Results demonstrated that WEB 17 is just as safe and effective as previous WEB generations. That included a low complication rate and no rebleeds at 30 days and at one year.
MicroVention reported an adequate occlusion rate of 86.5% for ruptured aneurysms (73.1% complete occlusion). The study reported a rate of 82.4% for unruptured aneurysms (57.1% complete occlusion) at one-year follow-up.
“MicroVention’s WEB Aneurysm Embolization System is now the most studied intrasaccular device available today, underscoring our commitment to physicians and patients alike to provide innovative, advanced medical device technology coupled with long-term safety and effectiveness,” said Carsten Schroeder, president and CEO, MicroVention. “With over 10,000 units sold in the United States, WEB advances treatment of wide-neck bifurcation aneurysms with one intrasaccular device – clinically proven one and done treatment. We will continue to work side-by-side with leading physicians around the world to identify the evolving needs in patient care, and then transform those insights into innovative technologies that help to save patient lives.”
